Axillary hyperhidrosis:
Treatment of severe primary axillary hyperhidrosis in adults not adequately managed with topical agents.
Cervical dystonia:
Treatment of cervical dystonia in patients 16 years of age to reduce the severity of abnormal head position and neck pain.
Migraine, chronic, prevention:
Prophylaxis of chronic migraine headaches ((15 days/month with headache lasting 4 hours/day) in adults.
Neurogenic detrusor overactivity:
Treatment of neurogenic detrusor overactivity in pediatric patients 5 years of age who have an inadequate response to or who are intolerant to an anticholinergic medication.
Overactive bladder:
Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults who have an inadequate response to or who are intolerant to an anticholinergic medication.
Spasticity:
Treatment of spasticity in patients 2 years of age.
Strabismus and blepharospasm associated with dystonia:
Treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders, in patients 12 years of age.
Urinary incontinence due to detrusor overactivity :
Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (eg, spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

Neuromuscular Blocker Agent, Toxin; Ophthalmic Agent, Toxin
OnabotulinumtoxinA (previously known as botulinum toxin type A) is a neurotoxin produced by Clostridium botulinum, spore-forming anaerobic bacillus, which appears to affect only the presynaptic membrane of the neuromuscular junction in humans, where it prevents calcium-dependent release of acetylcholine and produces a state of denervation.

Onset of action (improvement):
Blepharospasm: ~3 to 4 days
Cervical dystonia: ~2 weeks
Spasticity: Focal and cerebral palsy related: <2 weeks
Duration:
Blepharospasm: ~3 to 4 months
Cervical dystonia: 3 to 4 months
Spasticity: ~3 to 3.5 months
Absorption:
Not expected to be present in peripheral blood at recommended doses following intramuscular (IM) injection
Time to peak:
Blepharospasm: 1 to 2 weeks
Cervical dystonia: ~6 weeks
Spasticity (focal): 4 to 6 weeks

Hypersensitivity to any botulinum toxin preparation or any component of the formulation; infection at the proposed injection site(s).

C; OnabotulinumtoxinA has not been detected systemically in peripheral blood at recommended doses following intramuscular injection.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.

Urinary tract infection, bacteriuria, urinary retention; Headache; Dysphagia; Neck pain; Upper respiratory tract infection; Blepharoptosis, ertical deviation of eyes

Blepharospasm: IM
1. Initial dose: 1.25 to 2.5 units injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and lateral pretarsal orbicularis oculi of lower lid.
2. Dose may be increased up to twice the previous dose if the response from the initial dose lasted ≦2 months; maximum dose per site: 5 units.
Cervical dystonia: IM
For dosing guidance, the mean dose is 236 units divided among the affected muscles in patients previously treated with botulinum toxin (maximum: ≦50 units/site).
Spasticity: IM
Individualize dose based on patient size, extent, and location of muscle involvement, degree of spasticity, local muscle weakness, and response to prior treatment.
Migraine, chronic, prevention: IM
Administer 5 units per 0.1 mL per site. Recommended total dose is 155 units once every 12 weeks.

Blepharospasm/strabismus: Children ≧12 years: Refer to adult dosing.
Cervical dystonia: Children ≧16 years: Refer to adult dosing.
Spasticity:
Children ≧2 years: IM: 4 units/kg (total dose) divided into two injections into medial and lateral heads of the gastrocnemius of affected leg; if clinically indicated, may repeat every 2 months (maximum dose: 200 units).
In diplegia, the recommended dose is 6 units/kg (total dose) divided between affected limbs.

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling.

1. Store unopened vials under refrigeration at 2°C to 8°C for up to 36 months or until the expiration date on the vial.
2. Extended storage information at room temperature may be available; contact product manufacturer to obtain current recommendations.
3. After reconstitution, store in refrigerator at 2°C to 8°C and use within 24 hours (does not contain a preservative).